



FOR IMMEDIATE RELEASE

## GenesisCare Clinical CRO Adopts Veeva Vault Clinical Applications to Accelerate and Scale Studies Globally

*Leading CRO using Veeva Vault eTMF, Veeva Vault CTMS, and Veeva Vault Payments to streamline clinical trial processes*

**SYDNEY, AU — Dec. 07, 2020 — Veeva Systems** (NYSE: VEEV) today announced that contract research organisation (CRO) GenesisCare Clinical CRO, founded by GenesisCare, has adopted **Veeva Vault eTMF**, **Veeva Vault CTMS**, and **Veeva Vault Payments** to drive efficient trial processes globally.

GenesisCare Clinical CRO provides an integrated CRO model with the GenesisCare Clinical Research Site Network for faster and better designed drug development. With Veeva Vault Clinical applications unified on a secure cloud platform, the CRO can safely streamline each step of their model and trial management process as they continue to grow.

For example, monitoring visit reports are created and reviewed in Vault CTMS (clinical trial management system). Once approved, the report is automatically filed in Vault eTMF (electronic trial master file) while payment tracking to clinical research sites is automated through Vault Payments.

“Vault Clinical Suite allows us to efficiently manage end-to-end operational processes in our clinical studies,” said Helen Ormandy PhD, Head of Global Clinical Operations CRO, GenesisCare Clinical CRO. “Veeva innovations will further enable our integrated model as we expand our range of services and global reach.”

Veeva Vice President R&D APAC, Chris Shim, noted that, “Clinical trials can be fragmented with different manual processes for sharing data, documents, and payments. Veeva clinical applications will help GenesisCare Clinical CRO to simplify trials and speed execution as they manage a growing number of studies.”

Vault eTMF, Vault CTMS, and Vault Payments are part of the **Veeva Vault Clinical Suite** and enable CROs to seamlessly share information and documents for better collaboration and increased efficiency throughout the study lifecycle. To learn more, visit [veeva.com/clinical](https://veeva.com/clinical).

### Additional Information

Connect with Veeva APAC on LinkedIn: [linkedin.com/showcase/veeva-systems-apac/](https://www.linkedin.com/showcase/veeva-systems-apac/)

Follow @veevasystems on Twitter: [twitter.com/veevasystems](https://twitter.com/veevasystems)

Like Veeva on Facebook: [facebook.com/veevasystems](https://facebook.com/veevasystems)

### About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. Veeva certifications include ISO 27001:2013 and ISO 27018: 2019 Information Security Management. For more information, visit [veeva.com](https://veeva.com).

### About GenesisCare Clinical CRO

GenesisCare Clinical CRO was founded by GenesisCare and is operated as an independent company to ensure its clinical independence from GenesisCare. GenesisCare is a leading provider of cancer care in Australia, the UK, Spain and the USA, and the leading provider of cardiovascular care throughout Australia. GenesisCare Clinical CRO supports traditional full-service CRO offerings and is connected through GenesisCare to offer coordination of research services including Nuclear Medicine

and Central Imaging Services, and internal or external investigator sites. In addition, GenesisCare Clinical CRO supplies de-identified Real World Data through clinical registry build and management, and integration of EMR, patient portals and eCRFs. For more information, visit [genesiscare.com/au/clinical-cro/](https://genesiscare.com/au/clinical-cro/).

### **Forward-looking Statements**

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended July 31, 2020. This is available on the company's website at [veeva.com](https://veeva.com) under the Investors section and on the SEC's website at [sec.gov](https://sec.gov). Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

### **Contact:**

Brittagh Lynn  
Veeva Systems APAC  
+61 435 922 069  
[brittagh.lynn@contractor.veeva.com](mailto:brittagh.lynn@contractor.veeva.com)

Bec Sands  
Polkadot Communications  
+61 416 119 858  
[bec@polkadotcomms.com.au](mailto:bec@polkadotcomms.com.au)